GlassScriptPhysician profile
Channaiah Srikanth Mysore
NPI 1881900652
$5,286.95
in general payments reported to CMS, 2019-2025
48 companies · $51.84 in 2025
The $51.84 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $288 · 2020: $397 · 2021: $1,593 · 2022: $2,072 · 2023: $885 · 2025: $51.84.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $937.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $936.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $473.48 | 2021-2025 | |
| Biogen, INC. | $363.46 | 2019-2023 | Vumerity |
| Allergan, INC. | $343.79 | 2020-2022 | |
| Ucb, INC. | $334.79 | 2021-2023 | Fintepla, Briviact |
| Novartis Pharmaceuticals Corporation | $324.60 | 2020-2023 | |
| Sk Life Science, INC. | $314.34 | 2020-2023 | |
| Emd Serono, INC. | $297.77 | 2019-2023 | Mavenclad |
| Teva Pharmaceuticals USA, INC. | $280.33 | 2019-2023 | Austedo |
| Amneal Pharmaceuticals LLC | $235.61 | 2020-2023 | Rytary |
| Eisai INC. | $229.13 | 2021-2023 | |
| Neurocrine Biosciences, INC. | $160.02 | 2021-2023 | Ingrezza |
| Genentech USA, INC. | $158.17 | 2021-2022 | |
| Lilly USA, LLC | $150.19 | 2019-2023 | Amyvid, Emgality, Reyvow |
| Sunovion Pharmaceuticals INC. | $142.14 | 2021-2022 | |
| Genzyme Corporation | $140.47 | 2019-2022 |
Show all 48 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Channaiah Srikanth Mysore listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.